

COVID-19 Update

Grant Colfax, MD
Director of Health

April 6, 2021

Cumulative Cases and Deaths



SF COVID cases have plateaued



Population Characteristics: **Positive Cases**

Race/Ethnicity



Age Groups



Sexual Orientation



Gender



Key Health Indicators

Category	Key Question	Indicator	Triggers to raise or lower level	Level 1 New Normal	Level 2 Low Alert	Level 3 Moderate Alert	Level 4 High Alert
Health Care System	Are there early signs of an increase in hospitalizations?	Rate of increase in total COVID+ hospitalizations	Increase or decrease to meet new threshold over a 7-day period	**-4%** <10%	10-15%	15-20%	<10%
	Do we have capacity to treat severe cases?	Acute care bed available capacity	Meet threshold for over 7 days	**25%** >15%	10-15%	5-10%	<5%
	Do we have capacity to treat severe cases?	ICU bed available capacity	Meet threshold for over 7 days	**35%** >20%	15-20%	10-15%	<10%
Disease Situation	Are there early indicators of an increase in COVID-19 disease?	Number of new cases per day/ 100,000 population	Increase or decrease to meet new threshold over a 7-day period	<1.8	**3.8** 1.8-4.0	4.0-6.0	>6
	Are we testing enough to detect cases?	Tests per day	Meet threshold for over 7 days	**5,124** >1,800	1,800-1,400	1,400-700	<700
Disease Control	Do we have robust case investigation?	90% of new cases reached	Meet threshold for over 7 days	>90%	**85%** 80-90%	65-80%	<65%
	Do we have robust contact tracing?	90% of named contacts reached	Meet threshold for over 7 days	>90%	**82%** 80-90%	65-80%	<65%
	Are we protecting health care workers?	Percent of essential PPE with greater than a 30-day supply	Increase or decrease to meet new threshold over a 7-day period	**100%** 100%	85-100%	60-85%	<60%

Hospitalizations



Mean age of hospitalized patients



Vaccination of SF Residents

Estimated SF residents over 16 (vaccine approved for 16+ only)	San Franciscans over 16 who have received at least one dose	San Franciscans over 16 who have completed a vaccine series
768,789	64%	42%

All San Franciscans vaccinated with at least one dose from any provider	All San Franciscans who completed a vaccine series (second or only dose) from any provider
493,507	319,705



Vaccination administration = 10,400/day rolling average



- J&J remains on hold
- Pfizer files for EUA modification for 12-15 year olds
- Vaccine supply reduced for April
  - Near term supply challenges at the National level
  - LHJ's and providers will see a 35% reduction, likely through April

J&J Vaccine Pause – April 13

- SF is following FDA & CDC recommendation to pause distribution and administration of Johnson & Johnson vaccine, following 6 initial cases of blood clots among women who received it. To date:
  - Rare event: 6.8 million doses administered
  - Symptoms first occur within 2 weeks of dose of initially reported cases
- SF has administered over 33,000 J&J doses with no known events
- People who have received J&J should contact their provider if they experience severe headache, abdominal pain, leg pain, or shortness of breath within 3 weeks of their vaccination
- This pause will not have a significant effect on current vaccination efforts; the City has received very limited supply of J&J

Vaccine Progress & Challenges

- In SF, 64% of eligible residents vaccinated with at least 1 dose. 42% of eligible residents have completed their vaccinations. In comparison:
  - **US**: 39.5% received at least 1 dose; 25.4% fully vaccinated
  - **CA**: 52% received at least 1 dose; 31.4% fully vaccinated

- SF has received over 1 million vaccine doses and administered over 800k
  - However, rolling average of daily doses has decreased over past 2 weeks, commensurate with reduction in vaccine supply.
  - Allocations for this week are lowest since late February
  - Despite reduced delivery of vaccines, we project 70% of eligible residents will receive at least one dose by end of April
  - Continual, iterative efforts to provide low barrier access to vaccines and to address vaccine hesitancy